Value and goals of treat-to-target in systemic lupus erythematosus: Knowledge and foresight

Lupus

Volumn 24, Issue 4-5, 2015, Pages 507-515

  Doria, A ^a   Gatto, M ^a   Iaccarino, L ^a   Punzi, L ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Corticosteroid tapering; Low disease activity; Outcome; Remission; Systemic lupus; Target

Indexed keywords

CORTICOSTEROID;

ARTICLE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY SCORE; DISEASE EXACERBATION; EARLY DIAGNOSIS; HUMAN; MEDICATION COMPLIANCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SLEDAI; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO TREATMENT; DISEASE COURSE; DISEASE MANAGEMENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84925610359     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314559087     Document Type: Article

References (54)

1. Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: Treating-to-target and definition of treatment goals. Autoimmun Rev 2014; 13: 770-777.
2. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-967.
3. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology 2012; 51: 491-498.
4. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search. Ann Rheum Dis 2010; 69: 638-643.
5. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637.
6. Rydèn L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
7. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014; 30: 485-501.
8. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.
9. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of a tight control for rheumatoid arthritis (the TICORA study): A single-blind randomized controlled trial. Lancet 2004; 364: 263-269.
10. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-1449.
11. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: A multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 1294-1298.
12. Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005; 9: iii-iv, ix-x, 1-78.
13. Raffeiner B, Botsios C, Ometto F, et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clin Exp Rheumatol. 2014 [Accepted for publication on 29th July 2014].
14. Pincus T, Castrejòn I, Bergman MJ, Yazici Y. Treat-to-target: Not as simple as it appears. Clin Exp Rheumatol 2012; 30(Suppl 73): S10-S20.
15. Mosca M, Boumpas D, Bruce IN, et al. Treat-to-target in systemic lupus erythematosus: Where are we today? Clin Exp Rheumatol 2012; 30(Suppl 73): S112-S115.
16. Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: Relation to disease activity and damage accrual. Lupus 2007; 16: 309-317.
17. Urowitz MB, Gladman DD, Tom BD, Ibañez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-2158.
18. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009; 36: 560-564.
19. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 93-96.
20. Nived O, Jönsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29: 1398-1400.
21. Zen M, Bassi N, Nalotto L, et al. Disease activity patterns in a monocentric cohort of SLE patients: A seven-year follow-up study. Clin Exp Rheumatol 2012; 30: 856-863.
22. Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish population-based lupus cohort: An 8-year prospective study. Lupus 2010; 19: 239-246.
23. Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-1959.
24. Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2012; 64: 132-137.
25. Petri M, Bechtel B, Dennis G, et al. Burden of corticosteroid use in patients with systemic lupus erythematosus: Results from a Delphi panel. Lupus 2014; 23: 1006-1013.
26. Gaujoux-Viala C, Gossec L. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. Ann N Y Acad Sci 2014; 1318: 32-34.
27. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168-1172.
28. Steiman AJ, Urowitz MB, Ibañez D, Papneja A, Gladman DD. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014; 41: 1808-1816.
29. Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32: 1467-1472.
30. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-956.
31. Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: When early is early. Autoimmun Rev 2010; 10: 55-60.
32. Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53.
33. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22: 2531-2539.
34. Laskari K, Tzioufas AG, Antoniou A, Moutsopoulos HM. Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol 2011; 38: 1304-1308.
35. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: Long-term follow-up. Nephrol Dial Transplant 2006; 21: 1541-1548.
36. Mosca M, Tani C, Aringer M. Withdrawal of therapy in non-renal systemic lupus erythematosus: Is this an achievable goal? Clin Exp Rheumatol 2013; 31(4 Suppl 78): S71-S74.
37. Khanna D, Oh M, Furst DE, et al. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007; 57: 440-447.
38. Porter D, Dale J, Sattar N. How low to aim in rheumatoid arthritis? Learning from other disciplines. Ann Rheum Dis 2014; 73: 480-482.
39. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med 2010; 170: 1037-1044.
40. Wakefield RJ, D'Agostino MA, Naredo E, et al. After treat-totarget: Can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis 2012; 71: 799-803.
41. Zabaleta-Lanz ME, Muñoz LE, Tapanes FJ, et al. Further description of early clinically silent lupus nephritis. Lupus 2006; 15: 845-851.
42. Alvarado A, Malvar A, Lococo B, et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 2014; 23: 840-847.
43. Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34: 530-539.
44. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264.
45. Pons-Estel GJ, Wojdyla D, McGwin Jr G, et al. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics Classification criteria in two multiethnic cohorts: A commentary. Lupus 2014; 23: 3-9.
46. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.
47. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 3623-3632.
48. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012; 64: 511-518.
49. Gladman DD, Ibañez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: Data from an observational cohort study. J Rheumatol 2013; 40: 630-633.
50. Touma Z, Urowitz MB, Ibañez D, Gladman DD. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol 2014; 41: 688-697.
51. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
52. Pope JE, Haraoui B, Rampakakis E, et al. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: Results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res (Hoboken) 2013; 65: 1401-1409.
53. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: Ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore) 2004; 83: 1-17.
54. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682-2688.